Dr. Zhengfei Zhu 朱正飞
Chief Physician
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for common thoracic tumors, including lung cancer, esophageal cancer, and mediastinal tumors.
Dr. Zhu is Chief Physician and Deputy Administrative Director of the Radiation Therapy Center at Fudan University Shanghai Cancer Center. Dr. Zhu earned a PhD in Oncology from Fudan University in 2008 and completed two years as a visiting scholar at MD Anderson Cancer Center (2012–2014). Dr. Zhu has led over 10 national and provincial research projects, published more than 80 papers, and received the First Prize of the Shanghai Anti-Cancer Science and Technology Award.
Professional roles
- Deputy Director, Fudan University Institute of Thoracic Oncology
- Vice Chair, Tumor Radiation Physician Branch, Shanghai Medical Doctor Association
- Member, Committee on Tumor Radiotherapy, China Anti-Cancer Association
- Editorial Board Member, Chinese Journal of Metastatic Tumors
Name order: in Chinese the family name comes first (Zhu Zhengfei). Papers usually list the name as Zhengfei Zhu or Zhu Z.
Selected publications
157 papers on PubMed matched by name and affiliation; 64 as first or senior author since 2016. Most recent first- or senior-author papers:
- Precis Radiat Oncol, 2026 (senior author): Synergistic effects and clinical utilization of radioimmunotherapy for brain metastases from driver mutation-negative non-small cell lung cancer. PubMed 42609674
- Br J Cancer, 2026 (senior author): Identification of a distinct cluster of LY6E(+) macrophages in esophageal squamous cell carcinoma: functional phenotype, spatial interaction, and prognostic significance. PubMed 42056379
- Transl Lung Cancer Res, 2026 (senior author): Advances in the research on radiotherapy for lung cancer: a 2025 review. PubMed 41982692
- Int J Biol Sci, 2026 (senior author): Extracellular vesicles derived from irradiated tumor cells foster immunosuppressive macrophages formation to promote esophageal squamous cell carcinoma immune evasion. PubMed 41522343
- Clin Transl Med, 2025 (senior author): Radiation-induced extracellular vesicles from cancer-associated fibroblasts drive oesophageal squamous cell carcinoma metastasis via the miR-193a-3p/PTEN/Akt pathway. PubMed 40999795
- PLoS Med, 2025 (senior author): Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China. PubMed 40748918
- Cancer Immunol Immunother, 2025 (senior author): Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study. PubMed 40105955
- Exp Hematol Oncol, 2024 (senior author): Identification of a novel subtype of SPP1 + macrophages expressing SIRPα: implications for tumor immune evasion and treatment response prediction. PubMed 39696410
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion